Thomas T Amatruda
Overview
Explore the profile of Thomas T Amatruda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
211
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McLouth L, Zheng Y, Smith S, Hodi F, Rao U, Cohen G, et al.
Qual Life Res
. 2022 Aug;
32(1):183-196.
PMID: 36029412
Purpose: Trial E1609 demonstrated superior overall survival with ipilimumab 3 mg/kg (ipi3) compared to high-dose interferon (HDI) for patients with resected high-risk melanoma. To inform treatment tolerability, we compared health-related...
2.
Mai P, Miller A, Black A, Falk R, Boggess J, Tucker K, et al.
Am J Obstet Gynecol
. 2022 Feb;
227(1):61.e1-61.e18.
PMID: 35216968
Background: Risk-reducing salpingo-oophorectomy is an effective ovarian cancer risk reduction strategy. However, bilateral oophorectomy has also been associated with increased long-term nonneoplastic sequelae, effects suggested to be mediated through reductions...
3.
Dillman R, Cornforth A, Nistor G, McClay E, Amatruda T, Depriest C
J Immunother Cancer
. 2018 Mar;
6(1):19.
PMID: 29510745
Background: Despite improved survival following checkpoint inhibitors, there is still a potential role for anti-cancer therapeutic vaccines. Because of biological heterogeneity and neoantigens resulting from each patient's mutanome, autologous tumor...
4.
Dillman R, McClay E, Barth N, Amatruda T, Schwartzberg L, Mahdavi K, et al.
Cancer Biother Radiopharm
. 2015 Jun;
30(5):187-94.
PMID: 26083950
In patients with metastatic melanoma, sequential single-arm and randomized phase II trials with a therapeutic vaccine consisting of autologous dendritic cells (DCs) loaded with antigens from self-renewing, proliferating, irradiated autologous...
5.
Kim C, Economou S, Amatruda T, Martin J, Dudek A
Anticancer Res
. 2015 Jan;
35(1):301-9.
PMID: 25550564
Background/aim: Sentinel lymph node (SLN) biopsy provides useful prognostic information for patients with melanoma. The present study sought to determine the prognostic value of SLN tumor burden on overall survival...
6.
Dillman R, Cornforth A, Depriest C, McClay E, Amatruda T, De Leon C, et al.
J Immunother
. 2012 Sep;
35(8):641-9.
PMID: 22996370
Only 10% of metastatic melanoma patients survive 5 years, even though many can achieve substantial tumor reduction by surgical resection and/or radiation therapy and/or systemic therapy. An effective, nontoxic, consolidation...
7.
Koyanagi K, ODay S, Boasberg P, Atkins M, Wang H, Gonzalez R, et al.
Clin Cancer Res
. 2010 Apr;
16(8):2402-8.
PMID: 20371696
Purpose: Molecular biomarkers in blood are promising for assessment of tumor progression and treatment response. We hypothesized that serial monitoring of circulating tumor cells (CTC) with the use of multimarker...
8.
Lewis K, Robinson W, McCarter M, Pearlman N, ODay S, Anderson C, et al.
J Clin Oncol
. 2006 Jul;
24(19):3157-63.
PMID: 16809738
Purpose: To determine the relapse-free survival, overall survival, and response rate of patients with stage III melanoma treated with neoadjuvant biochemotherapy in a multicenter setting. Patients And Methods: Patients with...
9.
Koyanagi K, ODay S, Gonzalez R, Lewis K, Robinson W, Amatruda T, et al.
Clin Cancer Res
. 2006 Feb;
12(4):1137-43.
PMID: 16489066
Purpose: Microphthalmia transcription factor (Mitf), which is important in melanocyte development and melanoma growth, was assessed using real-time quantitative reverse transcription-PCR assay to investigate its expression as a marker for...
10.
Koyanagi K, ODay S, Gonzalez R, Lewis K, Robinson W, Amatruda T, et al.
J Clin Oncol
. 2005 Nov;
23(31):8057-64.
PMID: 16258104
Purpose: Circulating tumor cells (CTCs) in blood may be important in assessing tumor progression and treatment response. We hypothesized that quantitative real-time reverse transcriptase polymerase chain reaction using multimarker mRNA...